In an ambitious confluence of expertise, Alvotech and Dr. Reddy’s Laboratories have announced a partnership to co-develop, manufacture, and commercialize a biosimilar to the impactful cancer drug, Keytruda (pembrolizumab). This strategic alliance, underpinned by a shared vision of democratizing access to critical cancer therapies, aims to penetrate the vast global oncology market. Keytruda, a tour […]
Category: Biosimilars Development
Dr. Reddy’s, Alvotech Collaborate on Keytruda Biosimilar
In an exciting development that is likely to reshape the landscape of cancer therapeutics, Dr.Reddy’s Laboratories and Alvotech have announced a strategic partnership aimed at developing and commercializing a biosimilar version of Merck’s blockbuster cancer drug, Keytruda. This collaboration, formalized on June 5, 2025, is a robust testament to the growing synergy between pharmaceutical giants […]
